KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Payables (2016 - 2025)

Historic Payables for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $22.6 million.

  • Neogenomics' Payables fell 8957.72% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year decrease of 8957.72%. This contributed to the annual value of $222.4 million for FY2024, which is 99365.59% up from last year.
  • Latest data reveals that Neogenomics reported Payables of $22.6 million as of Q3 2025, which was down 8957.72% from $27.5 million recorded in Q2 2025.
  • Neogenomics' Payables' 5-year high stood at $222.4 million during Q4 2024, with a 5-year trough of $13.7 million in Q3 2022.
  • Over the past 5 years, Neogenomics' median Payables value was $20.5 million (recorded in 2022), while the average stood at $62.1 million.
  • As far as peak fluctuations go, Neogenomics' Payables skyrocketed by 118983.89% in 2024, and later tumbled by 8957.72% in 2025.
  • Quarter analysis of 5 years shows Neogenomics' Payables stood at $17.9 million in 2021, then rose by 14.45% to $20.5 million in 2022, then dropped by 0.86% to $20.3 million in 2023, then soared by 993.66% to $222.4 million in 2024, then tumbled by 89.83% to $22.6 million in 2025.
  • Its last three reported values are $22.6 million in Q3 2025, $27.5 million for Q2 2025, and $217.3 million during Q1 2025.